Anti-SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (7D603) is a Mouse antibody targeting SARS-CoV-2 (2019-nCoV) Spike Neutralizing. Anti-SARS-CoV-2 (2019-nCoV) Spike Neutralizing Antibody (7D603) can be used in ELISA.

IgG1

7D603

Virus

1. The ACE2-coated plate is incubated with SARS-CoV-2 Spike RBD-HRP (WT) and Anti-SARS-CoV-2 Spike RBD Neutralizing antibody. Percent inhibition is calculated based on the OD value by inhibiting RBD: ACE2 interaction. 
2. Direct ELISA was used to detect the binding ability of anti-RBD monoclonal antibody to RBD domain proteins of different SARS-CoV-2 Mutant Strains. Immobilized SARS-CoV-2 RBD proteins, at 2 μg/ml (100ul/Well) can bind Anti-RBD monoclonal antibody-HRP at 1 μg/ml (100ul/Well).

ELISA: 1:5000-10000

Monoclonal

Recombinant Protein: SARS-CoV-2 Spike S1 Protein

S

Spike glycoprotein

SARS Coronavirus

attaches the virion to the cell membrane by interacting with host receptor, initiating the infection (By similarity). Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (PubMed:32142651, PubMed:32075877, PubMed:32155444). Uses also human TMPRSS2 for priming in human lung cells which is an essential step for viral entry (PubMed:32142651). Proteolysis by cathepsin CTSL may unmask the fusion peptide of S2 and activate membranes fusion within endosomes.